Skip to content

Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

Sham-controlled Randomized Trial of Intra-articular Pulsed Radiofrequency Neuromodulation Versus Intra-articular Steroids for Painful Knee Osteoarthritis

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04238598
Enrollment
30
Registered
2020-01-23
Start date
2019-10-08
Completion date
2021-09-01
Last updated
2023-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Knee Osteoarthritis

Brief summary

To compare the efficacy of intra-articular pulsed radiofrequency to intra-articular steroids in patients with moderate-severe painful osteoarthritis of the knee.

Detailed description

Patients Adult patients with intractable knee pain for more than 6 months and radiographic evidence of grade II, III or IV knee osteoarthritis. Must not have had a knee injection or other interventional procedure for knee pain within the past 12 weeks. Must be on stable medications for the past 12 weeks and willing to keep medications stable for the first 12 weeks of the study. Study Design Pilot study will enroll 30 patients randomized 1:1:1. 1. Active control - intra-articular 4 milliliters 0.5% bupivacaine + 10mg dexamethasone + sham Pulsed Radiofrequency 2. Placebo control - intra-articular 5 milliliters 0.9% saline + sham Pulsed Radiofrequency 3. Treatment group - intra-articular 5 milliliters 0.5% bupivacaine + Pulsed Radiofrequency Methods Two 18-gauge radiofrequency needle with 10 millimeter active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency or sham-Pulsed Radiofrequency treatment will be administered. Subsequently, the injectate will be administered. Dexamethasone is selected as the corticosteroid as it is colorless and will be indistinguishable from the saline used in the Intra-articular Pulsed Radiofrequency and placebo groups.

Interventions

PROCEDUREPlacebo Intra-Articular Injection

Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Placebo Intra-Articular treatment will be administered.

PROCEDUREPulse Radiofrequency

Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Pulsed Radiofrequency treatment will be administered.

PROCEDUREStandard of Care Intra- Articular Injection

Two 20-gauge radiofrequency needle with 10mm active tip will be placed intra-articularly from an anterolateral and anteromedial approach to target the medial and lateral compartments. Once satisfactory fluoroscopic placement is noted, the Intra-Articular treatment will be administered.

Sponsors

Center For Interventional Pain and Spine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Intervention model description

test, active, control

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Capable of giving written informed consent * Patients aged 18 years or older * Patients with unilateral or bilateral knee pain for at least 3 months * Radiographic evidence of knee osteoarthritis * Appropriate candidate for steroid injection as determined by the investigator

Exclusion criteria

* Chronic knee pain caused by infection, inflammation, tumors, and fractures * A history of acute knee pain, previous knee surgery, connective tissue diseases, progressive neurologic disease or uncontrolled psychiatric disorders * The administration of steroids or hyaluronic acids within the last three months * Coagulation disorders * Local infection at the site of intervention planned * Active litigation related to this pain complaint

Design outcomes

Primary

MeasureTime frameDescription
Change in Visual Analogue Scale pain scores1-week, 1-, 3-, 6-, and 12-monthsEvaluates the level of pain. Minimum=0 Maximum=10, Larger number indicates worse outcome

Secondary

MeasureTime frameDescription
Change in Patient-Reported Outcomes Measurement Information System-29 and Western Ontario and McMaster Universities Osteoarthritis (Index)1-week, 1-, 3-, 6-, and 12-monthsEvaluates level of pain. For Patient-Reported Outcomes Measurement Information System-29, Minimum= 8 and Maximum=40. For Western Ontario and McMaster Universities Osteoarthritis (Index), Minimum=0 Maximum=20. Larger number indicates worse outcome
Change in Analgesic use1-week, 1-, 3-, 6-, and 12-monthsEvaluates number of medications, doses of medications
Change in Timed Up and Go Test1-week, 1-, 3-, 6-, and 12-monthsEvaluates physical mobility
Change in Progression to Surgery1-week, 1-, 3-, 6-, and 12-monthsEvaluates effectiveness of treatment

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026